At Debiopharm, every step we take is guided by one purpose: improving the lives of people affected by cancer and infectious diseases. As a privately-owned Swiss biopharmaceutical company, we’re driven by science, but above all, by the people behind every treatment — the patients and their families.
Through our unique “development only” model, we bring forward promising therapies and transform them into treatments that can reach those who need them most, faster.
Are you ready to pioneer regulatory pathways that bring life-saving therapies to patients faster?
We are currently looking for a dynamic Global Program Regulatory Lead to shape the future of our pipeline. In this pivotal role, you will be the strategic regulatory voice across Project Teams, defining global regulatory strategies for innovative medicines—including small molecules, biologics, and radiopharmaceuticals—from first-in-human studies through to registration. Your mission is to maximize compound value, navigate complex global regulatory landscapes, and accelerate early access for patients with high unmet medical needs. The role is part of the Regulatory Affairs team and will be based at our Headquarters in Lausanne, Switzerland.
Permanent role, full time | Lausanne, Switzerland
Executive Summary of Responsibilities
As the Global Program Regulatory Lead, you are responsible for defining, developing, and executing end-to-end global regulatory strategies across assigned development projects. Reporting to the Head of Regulatory Affairs, you will act as the primary interface with health authorities (FDA, EMA, and beyond), lead cross-functional regulatory sub-teams, support business development opportunities, and mentor junior regulatory professionals to drive operational excellence and compliance.
Key Tasks & Responsibilities
Requirements
Profile Required
Benefits
What We Offer
What to Expect in the Recruitment Process
If your application is selected, you’ll be invited to interviews with Talent Acquisition and the Hiring Manager via Teams, followed by a panel interview and reference checks. Communication is handled via Workable—check your spam folder for emails from *@outbound.workable.com.
Please contact our HR Department prior to submitting any profiles. We cannot accept unsolicited applications from agencies or recruiters.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe.
Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections.
Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®
If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!